New therapies for the treatment of systemic lupus erythematosus

被引：0

作者：

Gullick, Nicola ^{[1
]}

D'Cruz, David ^{[1
]}

机构：

[1] Guys Hosp, Dept Rheumatol, London SE1 9RT, England

来源：

EXPERT OPINION ON THERAPEUTIC PATENTS | 2007年 / 17卷 / 03期

关键词：

BAFF; B-cell depletion; immune activation; systemic lupus erythematosus;

D O I：

10.1517/13543776.17.3.299

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Systemic lupus erythematosus (SLE) is an autoimmune disease that, although uncommon, affects millions of patients worldwide. The foundation of therapy with antimalarials, corticosteroids and immunosuppressants, such as azathioprine or cyclophosphamide, has remained unchanged for a number of years. However, these drugs can be associated with significant side effects. Limitations of existing agents have driven interest in developing new therapies for SLE.

引用

页码：299 / 313

页数：15

共 155 条

[1]

A EINSTEIN COLL MED, 2006, Patent No. 2006026389

[2] LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus -: Results from a randomized, double-blind, placebo-controlled study [J].